PPP1R14D: A Potential Drug Target and Biomarker for PP1 Inhibition

Target Name: PPP1R14D

NCBI ID: G54866

PPP1R14D

PPP1R14D: A Potential Drug Target and Biomarker for PP1 Inhibition

PP1 (phosphoproteasome 1) is a key enzyme involved in the regulation of protein synthesis and degradation. It plays a crucial role in the control of cellular processes such as cell growth, apoptosis, and inflammation. The protein kinase PPP1R14D (PP1-PDK) is a key regulator of PPP1 activity and has been implicated in various cellular processes. PPP1R14D has been shown to be a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The Structure and Function of PPP1R14D

PP1R14D is a 21 kDa protein that is expressed in various tissues and cells, including brain, heart, liver, and cancer cells. It is a highly conserved protein that has homologs in various species, including humans, mouse, and rat. PPP1R14D is composed of a 21 kDa catalytic protein and a 15 kDa regulatory protein. The catalytic protein contains a catalytic domain, a nucleotide-binding oligomerization domain (NBD), and a C-terminal hypervariable region (HVR).

The NBD is a key region that interacts with various nucleotides to regulate PPP1 activity. The NBD contains a nucleotide-binding oligomerization domain (NBD) that consists of a nucleotide-binding oligomerization motif (NBM) and a nucleotide-binding oligomerization domain (NBD). The NBM is responsible for binding nucleotides, while the NBD is responsible for regulating the binding of nucleotides to the protein.

The C-terminal HVR is responsible for the regulation of PPP1 activity. It contains a series of conserved acidic and basic residues that are involved in the regulation of protein stability and activity. The HVR also contains a single mutable residue, Glu291, which is involved in the regulation of PPP1 activity.

Functional Analysis of PPP1R14D

PPP1R14D is a key regulator of PPP1 activity and has been shown to play a role in various cellular processes. PPP1R14D has been shown to regulate the activity of PPP1, which is involved in the regulation of protein synthesis and degradation. PPP1R14D has also been shown to regulate the activity of PPP1-PDK, which is involved in the regulation of PPP1 activity.

In addition to regulating PPP1 activity, PPP1R14D has also been shown to play a role in the regulation of cellular processes such as cell growth, apoptosis, and inflammation. For example, PPP1R14D has been shown to regulate the activity of the transcription factor, NF-kappa-B, which is involved in the regulation of cellular processes such as inflammation and stress responses.

PPP1R14D as a Potential Drug Target

PPP1R14D has been shown to be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Several studies have shown that PPP1R14D is a good candidate for inhibition due to its unique structure and its involvement in various cellular processes.

In cancer, PPP1R14D has been shown to play a role in the regulation of cell growth, apoptosis, and angiogenesis. Therefore, inhibition of PPP1R14D activity may be a useful strategy for the treatment of cancer. Several studies have shown that inhibition of PPP1R14D activity has led to the inhibition of

Protein Name: Protein Phosphatase 1 Regulatory Inhibitor Subunit 14D

Functions: Inhibitor of PPP1CA. Has inhibitory activity only when phosphorylated, creating a molecular switch for regulating the phosphorylation status of PPP1CA substrates and smooth muscle contraction

The "PPP1R14D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPP1R14D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets